| Product Name | CML ELISA kit (General species) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Carboxymethyl Lysine (CML). No significant cross-reactivity or interference between Carboxymethyl Lysine (CML) and analogues was observed. |
| Synonyms | N(6)-Carboxymethyllysine |
| Method | Competitive |
| Detection Range | 61.7-5,000ng/mL |
| Sensitivity | 25.9ng/mL |
| Target | CML |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Carboxymethyl Lysine (CML). No significant cross-reactivity or interference between Carboxymethyl Lysine (CML) and analogues was observed. |
| Sample Types | Serum, Plasma And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 50uL standard or sample to each well. And then add 50uL prepared Detection Reagent A immediately. Shake and mix.Incubate 1 hour at 37℃; 3.Aspirate and wash 3 times; 4.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 5.Aspirate and wash 5 times; 6.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 7.Add 50uL Stop Solution.Read at 450 nm immediately. |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Advanced Glycation End Products Induce Human Corneal Epithelial Cells Apoptosis through Generation of Reactive Oxygen Species and Activation of JNK and p38 MAPK Pathways;Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy.;Advanced glycation end-products accelerate the cardiac aging process through the receptor for advanced glycation end-products/transforming growth factor-β-Smad signaling pathway in cardiac fibroblasts;Inhibition of Advanced Glycation Endproduct Formation by Lotus Seedpod Oligomeric Procyanidins through RAGE-MAPK Signaling and NF-κB Activation in High-Fat-Diet Rats.;Association of serum N Îľ-Carboxy methyl lysine with severity of diabetic retinopathy;Hyperoside reduces albuminuria in diabetic nephropathy at the early stage through ameliorating renal damage and podocyte injury.;Increased levels of N(ε)- Carboxy methyl lysine (N(ε)-CML) are associated with topographic alterations in retinal pigment epithelium: A preliminary study;Long-term administration of advanced glycation end-product stimulates the activation of NLRP3 inflammasome and sparking the development of renal injury.;Plasma heparanase is associated with blood glucose levels but not urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage ;High intake of dietary advanced glycation end-products is associated with increased arterial stiffness and inflammation in subjects with type 2 diabetes.;Antiglycation and antioxidant activities of mogroside extract from (Swingle) fruits;Elevated advanced glycation end products are associated with subfoveal ellipsoid zone disruption in diabetic macular edema; |
| Supplier | Cloud Clone |
PROTOCOLS:
CEB977Ge All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
